A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of AK146D1 for Injection, an Anti-Trop2/Nectin4 Bispecific Antibody-drug Conjugate, in Patients With Advanced Solid Tumors
Latest Information Update: 30 Jul 2025
At a glance
- Drugs AK 146 D1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Akeso Biopharma
Most Recent Events
- 30 Jul 2025 New trial record